ARCHES post-hoc analyses: efficacy of ENZA + ADT in mHSPC by pattern of metastatic spread
Targeted screening and risk stratification of prostate cancer – updates from the IMPACT study
How should PSA screening be carried out to reduce the risk of harm to the patient
African Americans with prostate cancer respond better to abiraterone than Caucasians
10-year follow-up: the most effective treatment to ProtecT patients with localized prostate cancer?